Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Key catalysts approach for Orphazyme, Gemini and Immutep.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.